Pharmacological and genetic imaging of executive function deficits

Pharmacological and genetic imaging of executive function deficits - Pharmacological and genetic imaging of executive function deficits

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31059

Enrollment

Registered

2007-09-25

Start date

2007-10-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychische stoornissen: ontwikkelingsstoornissen (Autisme Spectrum Stoornissen) attention executive function deficits

Interventions

temporary, acute dopamine depletion by giving alpha-metyrosine (AMPT)

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 20 individuals with 22q11 deletion syndrome (DS) aged 18 till 40 years, 20 individuals with schizophrenia aged 18 till 40 years, 20 individuals with pervasive developmental disorder aged 18 till 40 years and 20 healthy volunteers, matched for age and gender, with no psychiatric history and no use of psychiatric medication.

Exclusion criteria

Exclusion criteria: Pregnancy and presence of metals that are not allowed in MRI-investigation

Design outcomes

Primary

Measure	Time frame
Blood Oxygen Level Dependant (BOLD) contrast measured during executive functioning tests within the MRI scanner	—

Secondary

Measure	Time frame
plasma levels of: * (HVA), * 3-methoxy-4 hydroxyphenethyleneglycol (MHPG), * VMA Urine levels of: * HVA * MHPG * VMA * dopamine * norepinephrine	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)